Podcasts

In this webinar, broadcast on 18th June 2020, our panel of experts discuss how we can start to optimally deliver key services as the pandemic eases. To view the webinar you need to be a registered user of the BJC so please log in or register.

In this webinar, broadcast on 2nd June 2020, our panel of experts discuss how the UK has adapted to new forms of service delivery during the COVID-19 pandemic and how this may help improve future patient care. To view the webinar you need to be a registered user of the BJC so please log in or register.

The DAPA-HF trial was hailed as a landmark study at the congress when the SGLT2 inhibitor, dapagliflozin, was shown to have an extraordinarily significant result versus placebo in reducing death and hospitilisation in patients with heart failure and reduced ejection fraction, both in those with and those without diabetes. The study is discussed by Professor David Hare (Professor of Medicine, University of Melbourne; Clinical Cardiologist, Austin Health, Victoria, Australia)

New guidance on diabetes, pre-diabetes and cardiovascular disease from the European Society of Cardiology (in collaboration with the European Association for the Study of Diabetes) was announced at the Congress. So what’s new? We find out from Professor Naveed Sattar (Professor of Metabolic Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow)

The AFIRE study has provided evidence for guidance, which has recommended that antiplatelet therapy can be stopped after one year in an antiplatelet/antiocoagulant combination therapy regime post-revascularisation. Professor Freek Verheugt (Professor of Cardiology, Heart-Lung Centre of the University Medical Centre of Nijmegen; Chairman of the Department of Cardiology, Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands) gives his thoughts on the implications of the study.

New European Society of Cardiology/European Atherosclerosis Guidelines on the management of dyslipidaemias were published at the Congress. Professor Alberico Catapano (Professor of Pharmacology, and Director of the Center of Epidemiology and Preventive Pharmacology, University of Milan, Italy) talks about the recommendations including new, more intensive goals for low-density lipoprotein cholesterol.